Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Go back to Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations| (NASDAQ: PVLA) | Delayed: 143.21 +1.03 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.18 | 52 Week High | $ | |||
| Open | $140.65 | 52 Week Low | $ | |||
| Day High | $144.10 | P/E | N/A | |||
| Day Low | $138.12 | EPS | $ | |||
| Volume | 134,812 | |||||
